文献速递白血病造血干细胞移植与细胞治疗

儿童白血病治疗后长期感染风险:基于行政健康数据的群体队列研究

Long-Term Risk of Infections After Treatment of Childhood Leukemia: A Population-Based Cohort Study Using Administrative Health Data.
PubMed 文献 · J Clin Oncol · 2019-08-08

该回顾性群体队列研究纳入1992至2015年加拿大安大略省确诊白血病且完成治疗后30天无复发生存的儿童,按5:1匹配一般人群,比较感染相对率。结果显示幸存者感染率显著升高(RR 1.51),且持续至5年以上;感染相关死亡风险显著增加。

要点

  • 儿童白血病治疗后感染率较一般人群升高(RR 1.51)。
  • 感染风险随随访时间延长而下降,但5年以上仍升高(RR 1.29)。
  • 未行HSCT者5年以上感染风险仍升高(RR 1.29)。

核心结论

  • 儿童白血病治疗史与感染风险增加显著相关。
  • 需进一步研究明确导致晚期感染的暴露因素。

研究设计与样本

  • 回顾性、群体队列研究,纳入1992至2015年加拿大安大略省确诊白血病且完成治疗后30天无复发生存的儿童。
  • 幸存者按出生年份、性别和城乡状态与一般人群5:1匹配,并按初始治疗是否包含HSCT分层。

主要发现

  • 共纳入2204例白血病幸存者和11020例对照。
  • 治疗完成后感染率较对照升高(RR 1.51;95% CI 1.45至1.57)。
  • 指数日期后不足1年感染RR 1.77(95% CI 1.69至1.86),1至4.99年RR 1.66(95% CI 1.62至1.71),5年及以上RR 1.29(95% CI 1.22至1.36)。
  • 初始治疗未包含HSCT者,指数日期后5年以上感染率仍升高(RR 1.29;95% CI 1.23至1.35)。
  • 感染相关死亡在全体幸存者(HR 149.3;95% CI 20.4至1091.9)和未行HSCT者(HR 92.7;95% CI 12.4至690.7)均显著增加。

临床怎么用

  • 儿童白血病治疗后应长期监测感染风险,尤其治疗完成后5年内。
  • 即使未行HSCT,治疗后5年以上仍需警惕感染风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Infections are a frequent complication during childhood leukemia treatment. Little is known about the infectious risk in survivors. We compared the relative rate (RR) of infections after treatment completion between pediatric leukemia survivors and the general population. METHODS: We performed a retrospective, population-based cohort study of children diagnosed with leukemia between 1992 and 2015 in Ontario, Canada, who were alive and relapse free 30 days after treatment completion (index date). Leukemia survivors were matched 5:1 with the general population by year of birth, sex, and rural status and stratified by initial treatment, including and excluding hematopoietic stem-cell transplantation (HSCT). The primary outcome was time to infections, as identified using validated diagnostic codes from administrative databases. Individuals were censored at the earliest of death, first relapse, loss to follow-up, or end of study. RESULTS: A total of 2,204 leukemia survivors were included and matched with 11,020 controls. The rate of infections was elevated after treatment completion compared with controls (RR, 1.51; 95% CI, 1.45 to 1.57) and at less than 1 year (RR, 1.77; 95% CI, 1.69 to 1.86); 1 to 4.99 years (RR, 1.66; 95% CI, 1.62 to 1.71), and 5 or more years (RR, 1.29; 95% CI, 1.22 to 1.36) from the index date. Among those whose initial treatment excluded HSCT, the rate remained elevated more than 5 years from the index date (RR, 1.29; 95% CI, 1.23 to 1.35). Infection-related death was significantly increased in leukemia survivors both among the entire cohort (hazard ratio, 149.3; 95% CI, 20.4 to 1,091.9) and among those without HSCT (hazard ratio, 92.7; 95% CI, 12.4 to 690.7). CONCLUSION: A significant association was found between a history of leukemia therapy and an increased risk of infections. Additional study is needed to establish which exposures in patients with leukemia lead to late infections.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pelland-Marcotte MC, Pole JD, Hwee J, et al. Long-Term Risk of Infections After Treatment of Childhood Leukemia: A Population-Based Cohort Study Using Administrative Health Data. J Clin Oncol. 2019. PMID: 31393747. doi:10.1200/JCO.19.00570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。